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1. Introduction
   Pharmaceutical inventions is singly stressing on delivery 
systems which enhance desirable therapeutic objectives 
while minimizing side effects. Oral drug delivery system 
represents one of the frontier areas of drug delivery 
systems. Such a dosage form manages common concern 
which exists in area of cost-efficient treatment, patient 
compliance, optimum drug delivery and bioavailability[1]. 
The site specific delivery of the drugs to the target sites 
has the potential to reduce the side effects and improved 
pharmacological response[1,2]. Targeting by magnetic 
microspheres i.e. incorporation of magnetic particles in to 
drug carriers (Polymers) and using an externally applied 
magnetic field is one way to physically direct these 
magnetic drug carriers to a desired site[3]. Drug targeting 
is the delivery of drugs to receptors or organ or any other 
specific part of the body to which one wishes to deliver 
the drug exclusively. Various nonmagnetic micro carriers 
(nanoparticles, microspheres and micro particles etc.) 
are successfully utilized for drug targeting but they show 
poor site specificity and are rapidly cleared off by RES 
(reticuloendothelial system) under normal circumstances. 
Magnetism play an important role in these case, magnetic 
particles composed of magnetite which are well tolerated 
by the body, magnetic fields are believed to be harmless 
to biological systems and adaptable to any part of the 
body[4]. Colon specific drug delivery systems have gained 
increasing attention for the treatment of diseases such as 
Crohn’s disease, ulcerative colitis and inflammatory bowel 
syndrome[5]. Magnetic microspheres will be formulated with 
an intension to produce a depot near the target organ, by 
placing a suitable magnet near it. From the depot, drug will 
be released slowly & carried to the target organ through 
blood. By localizing the drug carrier near the target organ, 
unwanted distribution of drug to non target organ can be 
avoided. This approach will localize the drug only at target 
site & minimize the drug-induced toxicity[6-9]. A major 
problem associated with all red blood cells (i.e. 7-8 mm), 
have a proper size range, and contain high concentrations 
of the magnetic material. However, the hydrophilic 
surface properties of magnetite compounds make it 
challenging to attain high magnetite content in hydrophobic 
biodegradable polymers such as Eudragit (S-100), ethyl 
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cellulose and chitosan[10]. 5-aminosalicylic acid is one of 
the drugs of choice to treat ulcerative colitis because of 
its potential activity. Mesalamine has been shown to block 
the production of interleukin-1 (IL-1) and tumor necrosis 
factor-a (TNF-a)[11,12]. Mesalamine is a potent inhibitor of 
the cyclo-oxygenase pathway, inhibiting the production 
of prostaglandin E2 in inflamed intestinal specimens. In 
the present study, ethyl cellulose, Eudragit and chitosan 
magnetic microspheres loaded with mesalamine are 
formulated to target the drug at its site of action. Eudragit 
S100 is an anionic copolymer of methacrylic acid and 
methyl methacrylate, the ratio of free carboxyl groups to the 
ester groups is approximately 1:2. It exhibits a dissolution 
threshold pH slightly above 7.2. Due to the pH-sensitive 
property of this polymer, it was selected to avoid the rapid 
dissolution of mesalamine during the initial transit of the 
microspheres through the gastric cavity and the upper small 
intestine. Chitosan is a high molecular weight polycationic 
polysaccharide derived from naturally occurring chitin by 
alkaline deacetylation. Chitosan has favorable biological 
properties such as non toxicity, biocompatibility and 
biodegradability. Magnetic chitosan microspheres have the 
ability to localize drugs by both biochemical and physical 
means
2. Materials and methods
2.1. Materials used
  Mesalamine was obtained as a gift sample from Ipca 
Laboratories Ltd .Ethyl cellulose (Central Drug House lab. 
New Delhi). All other chemicals and reagents used were of 
analytical grade.
2.2. Method
2.2.1. Preparation of magnetite
  The nitrogen gas was flushed through a 500 mL, two-
necked round-bottom flask fitted with a condenser. The 
flask was charged with 8.9 g (0.1 mol) of FeO, 9.94 g (0.05 
mol) of FeCl2•4H2O along with 250 mL deionized water and 
then 50 mL of 2 M NaOH was added while stirring vigorously. 
The reaction mixture was heated to reflux for 1-2 h. During 
the transformation of the pH, its pH fell from 14 to orange 
8-9 and a black precipitate was formed. After precipitation 
was completed, the Fe3O4 particles were washed with 
distilled water, filtered and dried under vacuum at room 
temperature[13].
2.2.2. Formulation of magnetic microspheres
  Microspheres were prepared by solvent evaporation 
technique. Accurately weighed but varying amounts of 
Eudragit S-100, ethylcellulose and chitosan were dissolved 
individually in 10 mL each of acetone over a cyclo-mixer, 
and accurately weighed drug was added to each of the 
polymer solution. 10 mg of magnesium stearate was then 
added to the solution of polymer and drug in acetone. Finally 
specified amount of magnetite was added to the drug-
polymer solution. The organic phase was poured drop-wise 
to 25 mL of 1:1 mixture of light and heavy liquid paraffin 
with vigorous stirring over a mechanical stirrer. High 
stirring rates of approximately 4 000 rpm were employed to 
obtain microspheres of smaller size. Stirring was continued 
for eight hours. 20 mL of hexane was added to the stirred 
contents. The batch was filtered and washed thrice with 
hexane, 10 mL each, to remove any adhering liquid paraffin 
from the surface of microspheres. Then, several washings 
with distilled water were given to remove any un-entrapped 
drug on the surface of the microspheres. Several batches of 
microspheres were prepared by varying drug-polymer ratio, 
keeping all other formulation factors constant (Table 1)[14].
2.3. Characterization of magnetic microspheres of 
5-aminosalicylic acid
2.3.1. Determination of percentage yield of microspheres
  Thoroughly dried microspheres were collected and weighed 
accurately. The percentage yield was calculated using 
formula[15]
Percentage yield = (Practical yield/Theoretical yield) 伊 100. 
Table 2 shows the percentage yield of the microspheres 
recovered.
Table 1
Formulation of magnetic microspheres.
Formulation code Magnetite (mg) Polymer Drug (mg)  Drug: Polymer ratio Method
F1 50 Chitosan (125mg) 125 1:1 Solvent evaporation
F2 50 Chitosan (166mg)   84 1:2 Solvent evaporation
F3 50 Chitosan (187mg)   63 1:3 Solvent evaporation
F4 50 Ethyl cellulose (125 mg) 125 1:1 Solvent evaporation
F5 50 Ethyl cellulose (166mg)   84 1:2 Solvent evaporation
F6 50 Ethyl cellulose (187 mg)   63 1:3 Solvent evaporation
F7 50 Eudragit (125mg) 125 1:1 Solvent evaporation
F8 50 Eudragit (166 mg)   84 1:2 Solvent evaporation
F9 50 Eudragit (187 mg)   63 1:3 Solvent evaporation
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Table 2
Percentage yield of formulations of magnetic microspheres.
S.no. Formulation code Percentage yield
1 F1 70.96
2 F2 74.19
3 F3 80.64
4 F4 64.50
5 F5 72.58
6 F6 74.10
7 F7 67.74
8 F8 73.54
9 F9 77.41
 
2.3.2. Micromeritic properties
  Accurately weighed microspheres were poured gently 
through a glass funnel into a graduated cylinder exactly to 
10 mL mark. Initial volume was noted. Bulk density and 
tapped density were noted using tapping method using 10 
mL measuring cylinder. Angle of repose (毴), Hausner’s ratio 
(H) and Carr’s index (% C) were calculated to study the flow 
properties of microspheres by using following 
formulas: 毴= tan−1h/r; Where, h is height and r is radius of 
the pile, respectively. 
H=Dt/Db 
% C = Dt-Db/Dt ×100 
  Where, Dt is tapped and Db is bulk density, respectively[16]. 
Table 3 shows the flow characteristics of the prepared 
microspheres
Table 3
Depiction of flow properties of magnetic microspheres.
Formulation 
code
Carr’s
index (%)
Hausner
ratio
Angle of
repose
Flow
character
F1   9.09 1.10 28.20 Excellent
F2 14.47 1.16 32.00 Good
F3 10.00 1.10 26.50 Excellent
F4 24.80 1.33 40.59 Passable
F5 25.30 1.33 41.18 Passable
F6 29.10 1.42 43.36 Poor
F7 10.00 1.10 28.20 Excellent
F8 20.00 1.20 26.50 Fair
F9 20.10 1.20 30.10 Fair
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Figure 1. Comparison of Carr’s index of formulations.
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Figure 2. Comparison of Hausner ratio of formulations.
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Figure 3. Comparison of angle of repose of formulations.
2.3.3. Drug entrapment efficiency
  Magnetic microspheres equivalent to 10 mg were weighed 
and suspended in 10 mL solution (0.5 mL 0.1 N HCl + 
9.5 mL PBS) for 5 min. The suspension was then filtered. 
Table 4
Entrapment efficiency of different drug: polymer ratio magnetic microspheres of 5-aminosalicylic acid.
Formulation code  Drug content (in 10 mg 
microspheres)
Drug content (in total 
microspheres recovered)
Drug content (in 100 mg 
microspheres)
Entrapment efficiency (%)
F1 5.00 110.00 50.00 88.00
F2 3.23   76.59 33.30 80.30
F3 2.83   70.80 28.30 94.40
F4 4.50   90.00 45.00 72.00
F5 3.16   71.20 31.66 84.70
F6 2.83   65.00 28.30 86.60
F7 4.60   97.80 46.60 78.20
F8 3.33   75.90 33.30 90.30
F9 2.83   67.90 30.00 90.56
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The digested homogenate was centrifuged for and the 
supernatant was analyzed for drug content by measuring 
the absorbance at 230 nm by UV-Vis spectrophotometer 
(UV1800 Shimadzu) after appropriate dilutions with PBS[17].
Entrapment efficiency = Experimental drug content / 
Theoretical drug content × 100
         Entrapment effciency
1
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3
4
5
6
7
8
9
  
Figure 4. Comparison of entrapment efficiency.
2.3.4. Particle size analysis
  It was carried out by using compound microscope. Dried 
magnetic microspheres were firstly redispersed in distilled 
water. These were then placed on a glass slide. The number 
of divisions of the calibrated eyepiece was counted by a 
micrometer using the stage micrometer[18]. Table 5 shows 
the particle size of the prepared formulations with different 
drug: polymer ratios.
Table 6
Particle size of formulations with codes F1 to F9.
S.no. Formulation code Particle size (毺m)
1 F1 153
2 F2 169
3 F3 184
4 F4 200
5 F5 215
6 F6 230
7 F7 153
8 F8 184
9 F9 200
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Figure 6. Particle size of formulations with formulation codes F4, F5, 
F6.
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Figure 7. Particle size of formulations with codes F7, F8, F9. 
2.3.5. Dissolution studies.
  Drug release tests were performed according to USP 
XXIV paddle method for each size fraction separately. 
Accurately weighed amounts (100 mg) of microspheres were 
introduced into 900 mL of PBS (phosphate buffer saline, pH 
7.4) and stirred with 100 rpm at (37.0依0.5) 曟. Five milliliters 
samples were withdrawn and filtered at selected time 
intervals. The concentration of mesalamine was determined 
spectrophotometrically at 230 nm[19]. 
Dissolution studies of formulations 
Table 7
In vitro release study of different formulations.
Formulation codes Drug : Polymer ratio Percentage release
F1 1:1 93.00
F2 1:2 82.40
F3 1:3 74.70
F4 1:1 80.66
F5 1:2 74.83
F6 1:3 72.05
F7 1:1 84.97
F8 1:2 78.37
F9 1:3 74.57
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Figure 8. Percentage release of formulations with codes F1, F2, F3.
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Figure 9. Percentage release of formulations with codes F4, F5, F6.
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Figure 10. Percentage release of formulations F7, F8, F9.
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Figure 11. Percentage release of formulations with drug: polymer ratio 
-1:1.
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Figure 12. Percentage release of formulations with drug: polymer 
ratio-1:2.
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Figure 13. Percentage release of formulations with drug: polymer ratio 
1:3.
Table 8
Swelling ratio of magnetic microspheres with respect to number of days.
Formulation code
Weight of microspheres
In dry state (Wd) (mg)
Weight of adsorbed water (WS) Swelling ratio (WS+Wd)/Wd
Day1 Day2 Day3 Day1 Day2 Day3
F1 10 1.0 2.0 2.0 1.1 1.2 1.2
F2 10 1.0 2.0 3.0 1.1 1.2 1.3
F3 10 1.0 2.0 5.0 1.1 1.2 1.5
F4 10 1.0 3.0 3.0 1.1 1.2 1.3
F5 10 1.0 2.0 3.0 1.1 1.3 1.3
F6 10 1.0 3.0 4.0 1.1 1.2 1.4
F7 10 1.0 1.0 2.0 1.1 1.1 1.2
F8 10 1.0 2.0 3.0 1.1 1.2 1.3
F9 10 1.0 2.0 3.0 1.1 1.3 1.3
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2.3.6. Measurement of swelling kinetics of magnetic 
microspheres
  Swelling kinetics of the magnetic microspheres was 
determined by swelling ratio (SR) at a given time. Dried 
microspheres were immersed in distilled water at each 
predetermined time at room temperature. Then, the sample 
was removed from distilled water and was frequently 
weighed after it was trapped with a filter paper to remove 
excess water on the surface. Thus, the wet weight of the 
microspheres was recorded during the swelling period at 
regular time intervals. The swelling ratio (SR), (Ws + Wd)/Wd, 
is defined as the ratio of the total weight of water in swollen 
microspheres to the weight of the dried microspheres, where 
Ws is the weight of adsorbed water and Wd is the weight of 
the microspheres at the dry state[20-22].
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Figure 14. Swelling ratio of microspheres with respect to number of days.
3. Result 
  Chitosan magnetic microspheres were found to be best in 
terms of in vitro release characteristics. Drug encapsulation 
efficiency is also better in chitosan microspheres. However 
swelling ratio varies with drug content also. As the more 
drugs are entrapped thus water molecules cannot acquire 
much space and thus results in low swelling ratio. 
4. Discussion
  Flow characteristics are also better in case of chitosan 
magnetic microspheres. Thus reticuloendothelial clearance 
can be minimized and site specificity can be increased.
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